Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

797
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
797
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Progression02:07

Tumor Progression

6.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.7K
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Cancer Vaccines01:30

Cancer Vaccines

595
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
595

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of <i>BRAF</i>-mutant advanced melanoma.

Journal of managed care & specialty pharmacy·2025
Same author

Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study.

Leukemia research·2024
Same author

Updates in the Management of Renal Cell Carcinoma.

Journal of the advanced practitioner in oncology·2022
Same author

Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2022
Same author

The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2021
Same author

Updates in the management of relapsed/refractory multiple myeloma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2021

Related Experiment Video

Updated: Nov 3, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

2019-2020 Drug Updates in Solid Tumors.

Kirollos S Hanna1

  • 1M Health Fairview and Mayo Clinic College of Medicine, Maple Grove, Minnesota.

Journal of the Advanced Practitioner in Oncology
|June 4, 2021
PubMed
Summary

Novel cancer medications offer new treatment options for solid tumors, expanding therapeutic strategies. This update covers their pharmacology, clinical trials, and managing potential adverse events in advanced practice settings.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Solid tumors represent a significant area of cancer research.
  • The development of novel therapeutic agents is rapidly evolving.
  • Understanding new drug indications and their clinical data is crucial for oncologists.

Purpose of the Study:

  • To provide an update on novel medications for solid tumors.
  • To discuss new and expanded indications for existing therapies.
  • To review clinical trial data and potential adverse events of new cancer drugs.

Main Methods:

  • Review of recent clinical trial data for novel oncology medications.
  • Discussion of pharmacological profiles and new indications.
  • Analysis of adverse event profiles and management strategies.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.7K

Related Experiment Videos

Last Updated: Nov 3, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.3K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.7K

Main Results:

  • Several novel medications show promise in treating solid tumors.
  • Expanded indications broaden the application of current therapies.
  • Identification of key adverse events and management approaches is essential.

Conclusions:

  • New therapeutic entities are expanding treatment options for solid tumors.
  • Advanced practice providers must be aware of pharmacology, efficacy, and safety.
  • Effective management of adverse events is critical for patient outcomes.